ArticleMolecular neurobiology2026
SirT2 Inhibition is Associated with Improvements in Depression-like Behavior and Memory Impairment in Olfactory Bulbectomized Mice.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increased silent information regulator protein 2 (SirT2) expression in the prefrontal cortex (PFC) has been reported to be associated with the development of depression; however, its functional contribution to depression-like behavior and memory impairment remains incompletely understood. In this study, we examined alterations in SirT2 expression in the PFC of olfactory bulbectomized (OBX) mice, a well-established model of depression, and evaluated the effects of AK-7, a selective SirT2 inhibitor, on OBX-induced depression-like behavior and memory impairment. On day 21 after surgery, OBX mice exhibited depression-like behaviors and memory impairment, as evidenced by prolonged immobility, reduced sucrose preference and spontaneous alternation, and shortened passive avoidance latency. Expression of SirT2 and pro-inflammatory microglial markers increased significantly, while those of Ac-FoxO1, PPARγ, arginase-1, MBP, MAG, CNPase, and Caspr were decreased, in the PFC of OBX mice. AK-7 administration attenuated these behavioral and molecular alterations. SirT2, Ac-FoxO1, and PPARγ showed spatial overlap with the microglial marker Iba1. AK-7 reduced microglial activation-associated morphological changes and attenuated OBX-induced disruption of node of Ranvier formation. These results suggest that AK-7 administration attenuates depression-like behavior and memory impairment, with concurrent improvements in node of Ranvier organization and modulation of microglial polarization in the PFC. Furthermore, our findings suggest that dysregulated SirT2 signaling may be involved, at least in part, in the development of depression-like behavior and comorbid memory impairment, and represents a potential avenue for further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.